Health·3,530 stories
The FDA is fast-tracking psychedelic treatments from Compass Pathways, Usona Institute, and Transcend Therapeutics, granting priority review vouchers to boost access to psilocybin and MDMA-like drugs
Eli Lilly is buying cash‑strapped cell‑therapy developer Kelonia Therapeutics for $3.2 billion, a deal that could double with milestone payments. Partner Bryan Roberts of Venrock explains how the star
Tenpoint Therapeutics has hired Stephen Lane as its new chief medical officer, bringing his Alcon experience and leadership of the Holland Foundation for Sight Restoration to the company. The appointm
President Trump’s drug policy overhaul moves medical marijuana to Schedule III and opens doors for psychedelics research, while CMS and FDA roll out a fast‑track Medicare pathway for breakthrough devi
President Trump closed the White House’s 17‑deal pharma pricing push with Regeneron, locking in a $27 billion U.S. drug‑development investment and a $225 price for Praluent on TrumpRx. At the same tim
Amid ongoing legal battles for the Trump administration, biotech headlines dominate: Sanofi’s multiple sclerosis therapy, turned down by the FDA, earned a positive recommendation from European regulat
A nine-month trial of personalized treatment plans for 73 people with mild cognitive impairment or early-stage dementia found that participants who received bespoke medical and lifestyle interventions
Physicists James Hefford and Matt Wilson have outlined a post‑quantum framework called QBox, where a hyperdecoherence process generates ordinary quantum mechanics while permitting causal indefinitenes
After a string of costly anti‑aging flops—from resveratrol’s $720 million demise at GSK to failed senolytics—researchers are finally testing a new approach: transient expression of Yamanaka factors to
Four years after the European Commission unveiled what was hailed as its largest-ever ban on toxic chemicals, a new report finds it has failed to begin regulating seven of 22 hazardous substance group
A newly confirmed mass grave in Jerash, Jordan, shows that hundreds of people died within days during the Plague of Justinian, offering direct archaeological and genetic evidence of the pandemic’s rap
After surviving three cash crises, CAR‑T pioneer Kelonia Therapeutics secured a $3.25 billion buyout by Eli Lilly, underscoring how high‑risk biotech turnarounds can translate into massive exits. At t
Amid mounting legal scrutiny and a foreign‑policy spotlight, Trump touts a domestic win: the final drug‑pricing pact with Regeneron, capping a series of 17 White House‑initiated deals. The agreement c
A mouse study led by researchers at the International Centre for Genetic Engineering and Biotechnology shows that the heart’s relentless beating creates mechanical stress that suppresses tumor growth,
Facing mounting legal scrutiny, President Trump shifted his agenda to drug policy, signing a $50 million executive order to fast‑track FDA approval of psychedelics and urging the DEA to lower marijuan
A new study in Science reveals that ancient octopus relatives up to 19 metres long used powerful, bone-crushing beaks to dominate Cretaceous oceans as apex predators who may have preyed on marine rept
Mouse experiments show respiratory syncytial virus (RSV) triggers an immune response that reduces breast cancer cells seeding in the lungs by 65-70%, with researchers identifying type I interferons an
Garijo steps in as Sanofi’s new CEO this month, inheriting a pipeline dominated by immunology after a series of lackluster trial outcomes. The biotech landscape also sees a gene‑therapy for deafness m
A new analysis of 617,186 participants from the UK Biobank and All of Us shows that Epstein‑Barr virus concentrates in B‑cells, hijacking them and triggering genes linked to multiple sclerosis. The wo
Northwestern researchers have followed a cohort of 80‑year‑olds dubbed SuperAgers, whose memory rivals that of people 30 years younger. Brain scans reveal a distinct neurobiological profile that resis
Curated health stories, every morning. Free.
No spam. Unsubscribe anytime.